Substance dependence

Addiction Policy Forum Launches Statewide Resource Center to Address the Opioid Crisis in Washington

Retrieved on: 
Monday, June 4, 2018
Substance dependence, Psychiatry, Health, Abnormal psychology, Drugs in the United States, Addiction, Psychiatric diagnosis, Opioid epidemic, Medicine, Substance use disorder, Internet addiction disorder, Draft:Facing Addiction

VANCOUVER, Wash., June 4, 2018 /PRNewswire/ -- The Addiction Policy Forum, a leading nonprofit tackling the opioid crisis, has launched its Addiction Resource Center (ARC) serving people across Washington who are struggling with substance use disorder, as well as their loved ones.

Key Points: 
  • VANCOUVER, Wash., June 4, 2018 /PRNewswire/ -- The Addiction Policy Forum, a leading nonprofit tackling the opioid crisis, has launched its Addiction Resource Center (ARC) serving people across Washington who are struggling with substance use disorder, as well as their loved ones.
  • The Addiction Resource Center was developed to fill that void in Washington."
  • The Addiction Resource Center is a comprehensive, interactive website to help individuals and families struggling with addiction learn about substance use disorders and access help.
  • In addition to developing accessible community resources, Addiction Policy Forum, which has chapters in 17 states and a national office in Washington, D.C., is committed to tackling addiction by affecting policy change at the local, state, and national levels, and raising awareness of the nationwide addiction crisis.

Addiction Policy Forum Launches Statewide Resource Center to Address the Opioid Crisis in Washington

Retrieved on: 
Monday, June 4, 2018
Substance dependence, Psychiatry, Health, Abnormal psychology, Drugs in the United States, Addiction, Psychiatric diagnosis, Opioid epidemic, Medicine, Substance use disorder, Internet addiction disorder, Draft:Facing Addiction

VANCOUVER, Wash., June 4, 2018 /PRNewswire/ -- The Addiction Policy Forum, a leading nonprofit tackling the opioid crisis, has launched its Addiction Resource Center (ARC) serving people across Washington who are struggling with substance use disorder, as well as their loved ones.

Key Points: 
  • VANCOUVER, Wash., June 4, 2018 /PRNewswire/ -- The Addiction Policy Forum, a leading nonprofit tackling the opioid crisis, has launched its Addiction Resource Center (ARC) serving people across Washington who are struggling with substance use disorder, as well as their loved ones.
  • The Addiction Resource Center was developed to fill that void in Washington."
  • The Addiction Resource Center is a comprehensive, interactive website to help individuals and families struggling with addiction learn about substance use disorders and access help.
  • In addition to developing accessible community resources, Addiction Policy Forum, which has chapters in 17 states and a national office in Washington, D.C., is committed to tackling addiction by affecting policy change at the local, state, and national levels, and raising awareness of the nationwide addiction crisis.

FDA Grants Breakthrough Device Designation to AutoGenomics' INFINITI® Neural Response Panel for the Identification of the Risk of Opioid Dependency

Retrieved on: 
Monday, June 4, 2018
Health, Medicine, Medical equipment, Substance dependence, Food and Drug Administration, United States Public Health Service, Medical device, Addiction, Opioid use disorder

The INFINITI Neural Response Panel is a qualitative in vitro diagnostic test for the identification of patients who may be at risk for opioid dependency.

Key Points: 
  • The INFINITI Neural Response Panel is a qualitative in vitro diagnostic test for the identification of patients who may be at risk for opioid dependency.
  • The Breakthrough Device Program is reserved for certain medical devices that demonstrate the potential to address unmet medical needs.
  • Under the Breakthrough Device Program, the FDA will provide its support to advance the INFINITI Neural Response Panel.
  • AutoGenomics conducted extensive research in the scientific literature of addiction studies that led to the development of the INFINITI Neural Response Panel.

S.A.F.E. Project US Invests in Law Enforcement Training for Opioid Response

Retrieved on: 
Saturday, June 2, 2018
Substance dependence, Drugs in the United States, Opioid epidemic, Enforcement, Health, Medicine

In an inaugural scholarship program through its Law Enforcement & Medical Response Line of Operation , S.A.F.E.

Key Points: 
  • In an inaugural scholarship program through its Law Enforcement & Medical Response Line of Operation , S.A.F.E.
  • Project US (Stop the Addiction Fatality Epidemic) provided three opportunities for law enforcement professionals to gain education, training and a network of support in the addiction epidemic.
  • "Offering training to members of law enforcement is a critical component to the S.A.F.E.
  • "The scholarships provided by S.A.F.E Project US help ensure law enforcement have the training they need to respond to the opioid epidemic.

HOW CAN WE SOLVE THE OPIOID CRISIS STARTING NOW? With An Opioid Crisis Summit Like No Other

Retrieved on: 
Friday, June 1, 2018
Substance dependence, Opioid epidemic, Opioid, Health, Ketones, RTT, Medicine, Chemistry

What do we know about the opioid crisis?

Key Points: 
  • What do we know about the opioid crisis?
  • On July 21-22, 2018, the definitive Opioid Crisis Summit presented by Mass Tort Nexus will convene a symposium to present a firsthand account as to the depth and severity of the crisis.
  • Summit attendees including attorneys, elected officials and healthcare officials will be giving specific information regarding the legal aspects of the Opioid Crisis as well.
  • See MDL 2804 Opiate Prescription Litigation US District Court of Ohio , for the National Prescription Opiate Litigation docket information.

Recovery Centers of America-Westminster Expands to 64 Beds to Meet Increasing Demand for Substance Use Disorder

Retrieved on: 
Thursday, May 31, 2018
Substance dependence, Psychiatry, Addiction, Substance abuse, Substance-related disorders, Psychiatric diagnosis, Substance use disorder, Heroin

This 16-bed increase allows the facility to treat the increasing number of patients struggling with substance use disorder in the New England area.

Key Points: 
  • This 16-bed increase allows the facility to treat the increasing number of patients struggling with substance use disorder in the New England area.
  • "RCA's mission has always been to help as many patients as possible on their journey to recovery.
  • Our 16 additional beds allow us to provide treatment to the people here in our community that desperately need our help."
  • RCA-Westminster offers comprehensive, individualized treatment services for a wide range of substance abuse issues, including alcohol, opiates, heroin, and methamphetamine.

As part of efforts to combat opioid crisis, FDA launches innovation challenge to spur development of medical devices ‒ including digital health and diagnostics ‒ that target pain, addiction and diversion

Retrieved on: 
Wednesday, May 30, 2018
Substance dependence, Health, Chemistry, Morphinans, Medicine, Opioid epidemic, Food and Drug Administration, Scott Gottlieb, Opioid, Naloxone

"Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in tackling the opioid crisis.

Key Points: 
  • "Medical devices, including digital health devices like mobile medical apps, have the potential to play a unique and important role in tackling the opioid crisis.
  • We must advance new ways to find tools to help address the human and financial toll of opioid addiction," said FDA Commissioner Scott Gottlieb, M.D.
  • "For example, better medical devices that can effectively address local pain syndromes can, in some cases, supplant the use of systemic opioids.
  • Developers accepted into the challenge will receive enhanced interactions with FDA review divisions during the development and evaluation of the proposed product.

Titan Pharmaceuticals And Braeburn Announce Mutual Termination Of License Agreement For Probuphine® For Opioid Dependence

Retrieved on: 
Wednesday, May 30, 2018
Cell signaling, Morphinans, Neurochemistry, Drug rehabilitation, Chemistry, RTT, Ethers, Phenols, Buprenorphine, Opioid use disorder, Opioid, Substance dependence

Under the terms of the termination agreement, Titan will regain all rights to the commercialization and clinical development of Probuphine in the U.S. and Canada.

Key Points: 
  • Under the terms of the termination agreement, Titan will regain all rights to the commercialization and clinical development of Probuphine in the U.S. and Canada.
  • In addition, the parties will immediately transfer to Titan all regulatory documentation and development data related to Probuphine.
  • "Meanwhile, we will ensure that Probuphine will continue to be available through established distribution channels for patients suffering from opioid use disorder."
  • The company's lead product is Probuphine, a novel and long-acting formulation of buprenorphine for the long-term maintenance treatment of opioid dependence.

Divurgent Supports CHIME's Task Force for National Opioid Crisis

Retrieved on: 
Thursday, May 24, 2018
Opioid epidemic, Substance dependence, Chime, Health, Medicine

The opioid crisis in the United States is having a devastating impact on individuals, their families, and the healthcare industry.

Key Points: 
  • The opioid crisis in the United States is having a devastating impact on individuals, their families, and the healthcare industry.
  • "The opioid crisis is sweeping our nation it's taken a hold on our communities, and Divurgent is truly honored to be part of this task force," said Colin Konschak, a founding task force member and supporter of the task force's continued effort to get a hold on this disease that is sweeping the nation.
  • "As a pharmacist, a member of CHIME, and long-time partner of healthcare organizations, I'm proud to be part of something as powerful as this task force."
  • CHIME sought to harness the talent and knowledge of its diverse membership for this task force, which was created in response to the magnitude of the opioid problem.

Altrix Medical Releases Life Saving App for Opioid Overdoses

Retrieved on: 
Wednesday, May 23, 2018
Medicine, Chemistry, RTT, Clinical medicine, Medical emergencies, Fissurellidae, Morphinans, Substance dependence, Altrix, Naloxone, Opioid epidemic, Opioid overdose

CENTREVILLE, Va., May 23, 2018 /PRNewswire/ --Today, Altrix Medical, LLC announced the release of NaloxoFind, a free app for iPhone and Android platforms to assist communities in battling the opioid epidemic.

Key Points: 
  • CENTREVILLE, Va., May 23, 2018 /PRNewswire/ --Today, Altrix Medical, LLC announced the release of NaloxoFind, a free app for iPhone and Android platforms to assist communities in battling the opioid epidemic.
  • Matthew Shaker, President of Altrix Medical, said "One hundred seventy-five people die from opioid overdoses every day, in part because naloxone isn't available when it's required.
  • About Altrix Medical, LLC: Altrix Medical LLC was founded in May 2013 with the singular goal of leveraging innovative technologies and imaginative ideas to prevent and cure disease.
  • Altrix Medical develops online applications and medical equipment with the goal of improving the quality of people's lives.